Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Camilla Poulsen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Danish Childhood Cancer Foundation.
Abstract (Originalsprache)
Background
Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management.
Methods
We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first relapse after initial treatment according to the NOPHO‐DBH AML 2012 protocol.
Results
The 4‐year overall survival (OS 4y ) was 44% (95% confidence interval [CI]: 36%–51%). OS 4y was 61% (CI: 51%–69%) in 133/188 patients who received stem cell transplantation (SCT) after reinduction therapy. Nineteen patients treated at the time of molecular relapse showed an excellent OS 4y of 84% (CI: 58%–95%). Patients with hematological relapse and MRD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Pediatric Hemato-Oncology, Rambam Health Care Campus, Haifa, Israel.
- Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital and The University of Hong Kong, Hong Kong, China.
- Hong Kong Pediatric Hematology and Oncology Study Group (HKPHOSG), Hong Kong, China.
- Department of Pediatric Hematology-Oncology, Ghent University Hospital, Gent, Belgium.
ORCID-Profile: Jonas Abrahamsson, Gertjan Kaspers, Cornelis Jan Pronk, Kristian Løvvik Juul-Dam
Förderung
- The Danish Childhood Cancer Foundation
Zitieren
APA
Poulsen, C., Sandahl, K. J., Karlsson, L., Abrahamsson, J., Arad-Cohen, N., Cheuk, D., De Moerloose, B., Fogelstrand, L., Navarro, J. M. F., Goemans, B. F., Jahnukainen, K., Kaspers, G., Kovalova, Z., Munthe-Kaas, M. C., Norén-Nyström, U., Palle, J., Pasauliene, R., Pronk, C. J., Saks, K., …, & Juul-Dam, K. L. (2026). Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70513
Vancouver
Poulsen C, Sandahl KJ, Karlsson L, Abrahamsson J, Arad-Cohen N, Cheuk D, et al. Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70513
BibTeX
@article{Poulsen2026,
author = {Poulsen, Camilla and Sandahl, Kristian Juul and Karlsson, Lene and Abrahamsson, Jonas and Arad-Cohen, Nira and Cheuk, Daniel and De Moerloose, Barbara and Fogelstrand, Linda and Navarro, Jose Maria Fernandez and Goemans, Bianca F and Jahnukainen, Kirsi and Kaspers, Gertjan and Kovalova, Zhanna and Munthe-Kaas, Monica Cheng and Norén-Nyström, Ulrika and Palle, Josefine and Pasauliene, Ramune and Pronk, Cornelis Jan and Saks, Kadri and Tierens, Anne and Hasle, Henrik and Juul-Dam, Kristian Løvvik},
title = {Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70513}
}
EUVIMED